Novel therapies in clinical use for the management of hyperlipidaemia
Optimal control of low-density lipoprotein cholesterol (LDLc) is identified as a major target in reducing cardiovascular disease burden globally. However, existing lipid-lowering therapies have not been able to achieve LDLc targets even in developed countries. Therefore, novel therapies for the mana...
Saved in:
| Main Author: | |
|---|---|
| Format: | Book |
| Published: |
Sri Lanka College of Internal Medicine,
2023-08-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_93b37e8d49894a44bc66a905b0f5e2b4 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a C. Mettananda |e author |
| 245 | 0 | 0 | |a Novel therapies in clinical use for the management of hyperlipidaemia |
| 260 | |b Sri Lanka College of Internal Medicine, |c 2023-08-01T00:00:00Z. | ||
| 500 | |a 10.4038/ajim.v2i2.105 | ||
| 500 | |a 2827-7260 | ||
| 520 | |a Optimal control of low-density lipoprotein cholesterol (LDLc) is identified as a major target in reducing cardiovascular disease burden globally. However, existing lipid-lowering therapies have not been able to achieve LDLc targets even in developed countries. Therefore, novel therapies for the management of hyperlipidaemia are being trialled. Currently, there are three main groups of newer medicines; bempedoic acid, PCSK9 inhibitors and inclisiran, in addition to statins and ezetimibe in use for the management of hyperlipidaemia. This article aims to introduce these newer medicines and their clinical use in the treatment of hyperlipidaemia. | ||
| 546 | |a EN | ||
| 690 | |a Novel therapies | ||
| 690 | |a Hyperlipidaemia | ||
| 690 | |a LDL | ||
| 690 | |a Bempedoic acid | ||
| 690 | |a PCSK9 inhibitors | ||
| 690 | |a Inclisiran | ||
| 690 | |a Internal medicine | ||
| 690 | |a RC31-1245 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Asian Journal of Internal Medicine, Vol 2, Iss 2 (2023) | |
| 787 | 0 | |n https://account.ajim.sljol.info/index.php/sljo-j-ajim/article/view/105 | |
| 787 | 0 | |n https://doaj.org/toc/2827-7260 | |
| 856 | 4 | 1 | |u https://doaj.org/article/93b37e8d49894a44bc66a905b0f5e2b4 |z Connect to this object online. |